Glaxo still in talks with FDA about Cervarix

Share this article:
GlaxoSmithKline said this week it was in discussions with the FDA about its Cervarix cervical cancer vaccine and hoped to issue soon an update on submitting the drug for approval, Reuters reported. Glaxo had previously planned to announce a timetable for filing Cervarix with the FDA before the end of 2005. “Discussions with the FDA are progressing, and we expect to be able to give an update soon,” a spokesman told Reuters. Cervarix is viewed as one of the most important new medicines in Glaxo’s pipeline. However, the drug appears set to reach the market behind Merck’s similar vaccine Gardasil, which has already been submitted for US and European approval. Industry analysts have been expecting Glaxo to file in the US sometime in 2006. Most say a first-half submission would be viewed as positive, whereas any delay into 2007 would be seen as negative. Both Cervarix and Gardasil have proved effective in clinical trials in preventing strains of human papillomavirus, which causes most cases of cervical cancer, the second-biggest cancer killer in women. Glaxo has said it believes the total cervical cancer vaccine market may be worth $4 billion to $7 billion in annual sales by 2010.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.